Our study showed that metformin, a first-line regimen of type 2 diabetes mellitus, had the potential to synergize with cisplatin to induce higher pro-apoptotic and anti-proliferative activity, through inhibition of NF-κB/HIF-1α axis in OSCC cells. This evidence concerns the gene NFKB1 and type 2 diabetes mellitus.